These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 12404688)

  • 21. Milnacipran in panic disorder with agoraphobia and major depressive disorder: a case report.
    Chen MH; Liou YJ
    Clin Neuropharmacol; 2011; 34(5):201-2. PubMed ID: 21926486
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Post-treatment emergent adverse events in depressed patients following treatment with milnacipran and paroxetine.
    Vandel P; Sechter D; Weiller E; Pezous N; Cabanac F; Tournoux A; Panconi E
    Hum Psychopharmacol; 2004 Dec; 19(8):585-6. PubMed ID: 15570574
    [No Abstract]   [Full Text] [Related]  

  • 23. Japanese experience with dual-action antidepressants.
    Tajima O
    Int Clin Psychopharmacol; 2002 Jun; 17 Suppl 1():S37-42. PubMed ID: 12369609
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A rapid improvement in obsessive-compulsive disorder with milnacipran in a patient with schizophrenia.
    Hung S; Hung GC
    J Clin Psychopharmacol; 2014 Oct; 34(5):653-4. PubMed ID: 25076421
    [No Abstract]   [Full Text] [Related]  

  • 25. Clinical potential of milnacipran, a serotonin and norepinephrine reuptake inhibitor, in pain.
    Leo RJ; Brooks VL
    Curr Opin Investig Drugs; 2006 Jul; 7(7):637-42. PubMed ID: 16869117
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The alpha 2A-adrenergic receptor gene polymorphism modifies antidepressant responses to milnacipran.
    Wakeno M; Kato M; Okugawa G; Fukuda T; Hosoi Y; Takekita Y; Yamashita M; Nonen S; Azuma J; Kinoshita T
    J Clin Psychopharmacol; 2008 Oct; 28(5):518-24. PubMed ID: 18794646
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Comparative studies with milnacipran and tricyclic antidepressants in the treatment of patients with major depression: a summary of clinical trial results.
    Kasper S; Pletan Y; Solles A; Tournoux A
    Int Clin Psychopharmacol; 1996 Sep; 11 Suppl 4():35-9. PubMed ID: 8923125
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A meta-analysis of clinical trials comparing milnacipran, a serotonin--norepinephrine reuptake inhibitor, with a selective serotonin reuptake inhibitor for the treatment of major depressive disorder.
    Papakostas GI; Fava M
    Eur Neuropsychopharmacol; 2007 Jan; 17(1):32-6. PubMed ID: 16762534
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Milnacipran for fibromyalgia.
    Dempsey J
    Issues Emerg Health Technol; 2008 Feb; (114):1-4. PubMed ID: 18354855
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Levomilnacipran: a newly approved drug for treatment of major depressive disorder.
    Mago R; Mahajan R; Thase ME
    Expert Rev Clin Pharmacol; 2014 Mar; 7(2):137-45. PubMed ID: 24524592
    [TBL] [Abstract][Full Text] [Related]  

  • 31. ACS chemical neuroscience molecule spotlight on savella.
    Hopkins CR
    ACS Chem Neurosci; 2010 May; 1(5):345. PubMed ID: 22778830
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Efficacy of levomilnacipran extended-release in improving functional impairment associated with major depressive disorder: pooled analyses of five double-blind, placebo-controlled trials.
    Sambunaris A; Gommoll C; Chen C; Greenberg WM
    Int Clin Psychopharmacol; 2014 Jul; 29(4):197-205. PubMed ID: 24667487
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The monoamine-mediated antiallodynic effects of intrathecally administered milnacipran, a serotonin noradrenaline reuptake inhibitor, in a rat model of neuropathic pain.
    Obata H; Saito S; Koizuka S; Nishikawa K; Goto F
    Anesth Analg; 2005 May; 100(5):1406-1410. PubMed ID: 15845695
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Efficacy and tolerability of milnacipran: an overview.
    Montgomery SA; Prost JF; Solles A; Briley M
    Int Clin Psychopharmacol; 1996 Sep; 11 Suppl 4():47-51. PubMed ID: 8923127
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Prediction of antidepressant response to milnacipran and fluvoxamine using pharmacogenetical methods].
    Higuchi H
    Nihon Shinkei Seishin Yakurigaku Zasshi; 2010 Apr; 30(2):71-6. PubMed ID: 20491280
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Therapeutic effects of milnacipran (serotonin noradrenalin reuptake inhibitor) on depression following mild and moderate traumatic brain injury.
    Kanetani K; Kimura M; Endo S
    J Nippon Med Sch; 2003 Aug; 70(4):313-20. PubMed ID: 12928711
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Effects of levomilnacipran ER on noradrenergic symptoms, anxiety symptoms, and functional impairment in adults with major depressive disorder: Post hoc analysis of 5 clinical trials.
    Blier P; Gommoll C; Chen C; Kramer K
    J Affect Disord; 2017 Mar; 210():273-279. PubMed ID: 28068615
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Effects of milnacipran and paroxetine on overactive bladder due to neurologic diseases: a urodynamic assessment.
    Sakakibara R; Ito T; Uchiyama T; Awa Y; Yamaguchi C; Hattori T
    Urol Int; 2008; 81(3):335-9. PubMed ID: 18931554
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Influence of painful physical symptoms in the treatment of Japanese patients with melancholic major depressive disorder: A prospective cohort study.
    Sekine A; Hozumi S; Shimizu T
    Psychiatry Res; 2016 Aug; 242():240-244. PubMed ID: 27294798
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Effectiveness of milnacipran for the treatment of chronic pain in the orofacial region.
    Ito M; Kimura H; Yoshida K; Kimura Y; Ozaki N; Kurita K
    Clin Neuropharmacol; 2010; 33(2):79-83. PubMed ID: 20375656
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.